MedTrace Logo

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

NCT02685852 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-05-06

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effectiveness of exenatide in adults experiencing episodes of hyperinsulinemic hypoglycemia following Roux-en-Y bariatric surgery.

Conditions

  • Hyperinsulinemic Hypoglycemia

Interventions

DRUG

Exenatide

Exenatide at a dose of 5 mcg

DRUG

Acarbose

Acarbose at a dose of 25 mg

DRUG

Exenatide Placebo

Placebo for Exenatide

DRUG

Acarbose Placebo

Placebo for Acarbose

Sponsors & Collaborators

Principal Investigators

  • Shalamar D Sibley, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-07-22
Completion
2019-07-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685852 on ClinicalTrials.gov